Century Therapeutics (IPSC) Short term Debt (2021 - 2026)

Century Therapeutics (IPSC) has reported Short term Debt for 5 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short term Debt changed N/A year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (changed N/A YoY), while the FY2025 annual figure was $3.8 million, changed N/A from the prior year.
• Short term Debt declined to $1.9 million in Q1 2026 per IPSC's latest filing, from $3.8 million in the prior quarter.
• Across five years, Short term Debt topped out at $10.3 million in Q1 2023 and bottomed at $1.6 million in Q2 2022.
• Historically, Short term Debt has averaged $5.2 million across 4 years, with a median of $4.0 million in 2022.
• On a YoY basis, Short term Debt climbed as much as 525.79% in 2022 and fell as far as 525.79% in 2022.
• Century Therapeutics' Short term Debt stood at $6.5 million in 2022, then soared by 58.37% to $10.3 million in 2023, then plunged by 63.51% to $3.8 million in 2025, then slumped by 48.39% to $1.9 million in 2026.
• Business Quant data shows IPSC's Short term Debt at $1.9 million in Q1 2026, $3.8 million in Q4 2025, and $8.3 million in Q3 2025.